CDN1163 is primarily researched for its potential therapeutic applications in the treatment of metabolic disorders, particularly type 2 diabetes. It functions as an allosteric activator of the sarco/endoplasmic reticulum calcium ATPase (SERCA), which plays a critical role in calcium homeostasis within cells. By enhancing SERCA activity, CDN1163 helps improve insulin sensitivity and glucose metabolism, making it a promising candidate for managing diabetes. Additionally, its ability to regulate calcium signaling may have broader implications in addressing other conditions linked to calcium dysregulation, such as cardiovascular diseases and neurodegenerative disorders. Ongoing studies aim to further explore its efficacy and safety for clinical use.